[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368917-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368917-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lymph-node-ratio-predicts-adjuvant-chemotherapy-benefit-in-esophageal-squamous-cell-carcinoma-abstract","Lymph Node Ratio Predicts Adjuvant Chemotherapy Benefit in Esophageal Squamous Cell Carcinoma - Abstract","","The lymph node ratio (LNR) is evaluated as a prognostic factor for guiding adjuvant chemotherapy after potentially curative resection in esophageal squamous cell carcinoma (ESCC). A retrospective cohort of 2267 ESCC patients treated from January 2010 to December 2017 was analyzed. Overall survival was assessed using Cox models, with LNR explored by restricted cubic splines and adjusted with propensity score matching. An LNR threshold of 11% defined benefit: patients below 11% gained significant OS benefit (HR 0.57), while those above 11% showed no OS benefit (HR 0.87).",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lymph-node-ratio-predicts-adjuvant-chemotherapy-benefit-in-esophageal-squamous-cell-carcinoma-abstract/368917/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lymph-node-ratio-predicts-adjuvant-chemotherapy-benefit-in-esophageal-squamous-cell-carcinoma-abstract/368917.png","ImageObject",300,407,{"name":42,"@type":43},"Anna Hans","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of this study regarding ESCC treatment?","Question",{"text":63,"@type":64},"To evaluate whether the lymph node ratio (LNR) can guide decisions about postoperative adjuvant chemotherapy in ESCC patients after resection.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study designed and which population was analyzed?",{"text":68,"@type":64},"A retrospective analysis included 2267 patients who underwent potentially curative surgery for ESCC at Sichuan Cancer Hospital and Institute between January 2010 and December 2017.",{"name":70,"@type":61,"acceptedAnswer":71},"What LNR threshold was identified and what did it mean for chemotherapy benefit?",{"text":72,"@type":64},"Restricted cubic spline analysis identified an LNR threshold of 11%. Patients with LNR below 11% showed significant overall survival benefit from adjuvant chemotherapy, while those above 11% did not.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368917,1790834754,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Lymph node ratio predicts adjuvant chemotherapy benefit in esophageal squamous cell carcinoma  \nJun Peng1,\\#,, Yi Wang2,\\#, Haoyue Hu3,\\#, Lei Wu2, Wei Dai1, Yehan Zhou4, Na Li5, Lin Peng1, Xuefeng Leng1, Xiang Zhuang*1,‡,, Qifeng Wang*,2,‡, Xiang Wang*, 1,‡,  \n1Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, 610041, China  \n2Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, 610041, China 3Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China  \n4Department of Pathology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, 610041, China  \n5Cancer Center of Suning Central Hospital, Suining, 629000, China  \n*Corresponding authors: Xiang Wang, MD, Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China, No.55, Section 4, South Renmin Road, Chengdu, 610041, [China. E-mail:](China. E-mail: wangxiang@scszlyy.org.cn)[ wangxiang@scszlyy.org.cn](China. E-mail: wangxiang@scszlyy.org.cn); Qifeng Wang, PhD, Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, No.55, Section 4, South Renmin Road, Chengdu, 610041, [China. E-mail:](China. E-mail: wangqifeng@scszlyy.org.cn)[ wangqifeng@scszlyy.org.cn](China. E-mail: wangqifeng@scszlyy.org.cn); Xiang Zhuang, PhD, Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China, No.55, Section 4, South Renmin Road, Chengdu, 610041, China. E-mail: [zhuangxiang1@scszlyy.org.cn](zhuangxiang1@scszlyy.org.cn).  \n\\#Co-first authors.  \n‡Contributed equally as joint senior authors.  \nAbstract  \nBackground: The lymph node ratio (LNR) has emerged as an important prognostic factor in various cancers, including esophageal squamous cell carcinoma (ESCC) . This study aimed to evaluate the utility of LNR in guiding decisions for adjuvant chemotherapy in ESCC patients following resection.  \nMaterials and Methods: A retrospective analysis was conducted on 2267 patients who underwent potentially curative surgery for ESCC at Sichuan Cancer Hospital and Institute between January 2010 and December 2017. Univariate and multivariate Cox proportional hazards regressions were used to assess factors influencing overall survival (OS), with LNR analyzed using restricted cubic splines (RCS) to explore its relationship with treatment and survival outcomes. Propensity score matching (PSM) was employed to adjust for biases between treatment groups. Results: Among the patients, 1416 underwent surgery alone (S group) and 851 received surgery plus adjuvant chemotherapy (S + CT group) . The median LNR was 3%, with an interquartile range of 0%-12% . RCS analysis identified an LNR threshold of 11%, below which patients showed a significant OS benefit from adjuvant chemotherapy (hazard ratio [HR]: 0. 57; 95% CI: 0.46-0.71; P\u003C 0.001) . However, patients with an LNR above 11% did not derive any OS benefit from chemotherapy (HR: 0.87; 95% CI: 0.70-1.09; P = 0.238) .  \nConclusion: These findings ","cbCair9MPmMo34dR","https://ap.wps.com/l/cbCair9MPmMo34dR","pdf",3070395,"English","# Abstract\n## Background\n## Materials and Methods\n## Results\n## Conclusion\n# Introduction\n## Current treatment context","[{\"question\":\"What is the purpose of this study regarding ESCC treatment?\",\"answer\":\"To evaluate whether the lymph node ratio (LNR) can guide decisions about postoperative adjuvant chemotherapy in ESCC patients after resection.\"},{\"question\":\"How was the study designed and which population was analyzed?\",\"answer\":\"A retrospective analysis included 2267 patients who underwent potentially curative surgery for ESCC at Sichuan Cancer Hospital and Institute between January 2010 and December 2017.\"},{\"question\":\"What LNR threshold was identified and what did it mean for chemotherapy benefit?\",\"answer\":\"Restricted cubic spline analysis identified an LNR threshold of 11%. Patients with LNR below 11% showed significant overall survival benefit from adjuvant chemotherapy, while those above 11% did not.\"}]","Lymph Node Ratio Predicts Adjuvant Chemotherapy Benefit in Esophageal Squamous Cell Carcinoma - Abstract | PDF",1790179206,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bd1a1ab7f935238cb2a8da6b6a16551.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e78f7c536225cead8e654f6836d6c8bd.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a54f7d3be710a73daedad976d428c78c.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10e02858817dcb6da17b676cba2c9dc4.webp",980,1287]